Novo Nordisk reported that Wegovy helped free about 40% of children from obesity in a Phase 3 trial, according to the provided report. The outcome adds to the expanding pediatric obesity data set for GLP-1–based therapies as payers and regulators continue to scrutinize long-term safety and durability. The trial result also intensifies competitive pressure across the incretin class, as companies increasingly tailor dosing regimens and endpoints for younger age groups—where trial designs and adherence patterns can differ from adult programs.